Skip to content

AI based screening for breast cancer

A Prospective Observational Study to evaluate the Clinical Performance of Thermalytix against Standard Breast Imaging Modalities for detecting breast malignancies in asymptomatic and symptomatic women

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/07/090943
Enrollment
10000
Registered
2025-07-15
Start date
Unknown
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

Intervention1: Thermalytix Breast Imaging device: Novel breast cancer detection tool based on artificial intelligence analysis of breast thermal images Control Intervention1: mammography and ultrasoun

Sponsors

Niramai Health Analytix Pvt Ltd, Bangalore
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Asymptomatic or symptomatic women who are capable of understanding the investigational nature of the study and all pertinent aspects of study capable of signing and providing written consent in accordance with institutional and federal guidelines In the situation where participant is unable to read or write, In this situation, the consent form will be read out to the participant in the local language and thumb print obtained willing and able to comply with scheduled visits, treatment plan, and follow up with research staff

Exclusion criteria

Exclusion criteria: Women who are pregnant or lactating Women who have had breast palpation within the past 72 hours Women who have had their menstrual cycle within 7 days Women with prior history of breast cancer, breast surgeries including implants; lumpectomy or surgery Women who are currently or who had breast cancer treatment including chemotherapy or radiotherapy in the last 6 months Women who are undergoing hormonal therapy Unable to complete study-related procedures Patients not willing to undergo USG/Biopsy/PET/MRI if indicated Incapable of or not willing to give consent

Design outcomes

Primary

MeasureTime frame
Sensitivity, specificity, negative & positive predictive values, diagnostic accuracy of Mythri-Thermalytix & CBE when compared to one or more of the following reference tests- breast ultrasound, MRI or histopathology Timepoint: at time of test & at one year

Secondary

MeasureTime frame
The agreement between / correlation of Mythri-Thermalytix, CBE & ultrasound diagnosisTimepoint: at time of test & after one year

Countries

India

Contacts

Public ContactProf Dr Shilpa Rao

Seth GS Medical College and KEM Hospital

ateeshilpa@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026